menu search

SNDX / Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023

Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remission rate of 23%, significantly higher than the current standard of care. It is expected that an NDA of revumenib for AML is expected before end of 2023; it is also being evaluated in other patient populations which could expand its potential. Read More
Posted: Oct 13 2023, 14:52
Author Name: Seeking Alpha
Views: 092114

SNDX News  

Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript

Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript more_horizontal

Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023

By Seeking Alpha
October 13, 2023

Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023

Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The tr more_horizontal

Syndax Pharmaceuticals fall despite positive leukemia

By Proactive Investors
October 2, 2023

Syndax Pharmaceuticals fall despite positive leukemia

Syndax Pharmaceuticals (NASDAQ:SNDX) Inc (Syndax Pharmaceuticals (NASDAQ:SNDX)) stock was on the back foot on Monday, after reporting results from a l more_horizontal

Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results

By Seeking Alpha
September 8, 2023

Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results

Syndax is making strides in the adoption of entinostat, a cancer therapeutic used in combination with immune checkpoint therapies. Syndax reported an more_horizontal

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 5, 2023

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, IR M more_horizontal

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 8, 2023

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Sharon Klahre - Head, Investo more_horizontal

Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why

By Zacks Investment Research
February 6, 2023

Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why

Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is on more_horizontal

Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why

By Zacks Investment Research
January 20, 2023

Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why

Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is on more_horizontal


Search within

Pages Search Results: